Concepts (236)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Multiple Sclerosis | 22 | 2024 | 207 | 4.070 |
Why?
|
| Multiple Sclerosis, Relapsing-Remitting | 12 | 2025 | 33 | 1.830 |
Why?
|
| Proteomics | 1 | 2024 | 263 | 0.810 |
Why?
|
| Cerebellar Diseases | 1 | 2020 | 9 | 0.680 |
Why?
|
| Biomarkers | 3 | 2024 | 1306 | 0.670 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2020 | 33 | 0.670 |
Why?
|
| Infectious Mononucleosis | 1 | 2020 | 33 | 0.660 |
Why?
|
| Leukoencephalopathy, Progressive Multifocal | 1 | 2019 | 18 | 0.660 |
Why?
|
| Intracranial Thrombosis | 1 | 2019 | 27 | 0.650 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2020 | 89 | 0.630 |
Why?
|
| Venous Thrombosis | 1 | 2019 | 110 | 0.610 |
Why?
|
| Dystonia | 1 | 2018 | 13 | 0.600 |
Why?
|
| Sjogren's Syndrome | 1 | 2018 | 24 | 0.590 |
Why?
|
| Antibodies, Monoclonal, Humanized | 4 | 2020 | 219 | 0.570 |
Why?
|
| Multiple Sclerosis, Chronic Progressive | 4 | 2024 | 14 | 0.540 |
Why?
|
| Central Nervous System Diseases | 2 | 2016 | 56 | 0.500 |
Why?
|
| Arthritis, Juvenile | 1 | 2015 | 7 | 0.490 |
Why?
|
| Etanercept | 1 | 2015 | 32 | 0.490 |
Why?
|
| Sarcoidosis | 1 | 2015 | 30 | 0.480 |
Why?
|
| Immunosuppressive Agents | 4 | 2020 | 365 | 0.470 |
Why?
|
| Uveitis | 1 | 2015 | 32 | 0.470 |
Why?
|
| White Matter | 3 | 2023 | 114 | 0.460 |
Why?
|
| Bipolar Disorder | 1 | 2016 | 243 | 0.440 |
Why?
|
| Thrombocytopenia | 1 | 2014 | 45 | 0.440 |
Why?
|
| Olivary Nucleus | 1 | 2013 | 3 | 0.440 |
Why?
|
| Cognition Disorders | 1 | 2015 | 215 | 0.430 |
Why?
|
| Magnetic Resonance Imaging | 9 | 2024 | 2060 | 0.430 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2013 | 38 | 0.420 |
Why?
|
| Positron-Emission Tomography | 4 | 2024 | 200 | 0.420 |
Why?
|
| Lymphoma | 1 | 2013 | 99 | 0.410 |
Why?
|
| Antirheumatic Agents | 1 | 2015 | 214 | 0.410 |
Why?
|
| Humans | 41 | 2025 | 59360 | 0.400 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2015 | 588 | 0.400 |
Why?
|
| Middle Aged | 20 | 2025 | 16317 | 0.390 |
Why?
|
| Adult | 18 | 2025 | 15669 | 0.370 |
Why?
|
| Male | 23 | 2025 | 27739 | 0.370 |
Why?
|
| Receptors, GABA | 2 | 2024 | 11 | 0.370 |
Why?
|
| Quality of Life | 2 | 2023 | 1137 | 0.360 |
Why?
|
| Female | 23 | 2025 | 30705 | 0.330 |
Why?
|
| Cross-Sectional Studies | 4 | 2024 | 2373 | 0.280 |
Why?
|
| Pyrimidines | 2 | 2019 | 131 | 0.280 |
Why?
|
| Biomedical Research | 2 | 2022 | 256 | 0.260 |
Why?
|
| Vertebral Artery | 1 | 2006 | 27 | 0.260 |
Why?
|
| Diagnosis, Differential | 3 | 2019 | 937 | 0.250 |
Why?
|
| Immunologic Factors | 3 | 2020 | 103 | 0.250 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2006 | 178 | 0.240 |
Why?
|
| Crotonates | 2 | 2025 | 4 | 0.230 |
Why?
|
| Toluidines | 2 | 2025 | 4 | 0.230 |
Why?
|
| Meninges | 1 | 2024 | 10 | 0.230 |
Why?
|
| Alemtuzumab | 4 | 2023 | 11 | 0.190 |
Why?
|
| Inflammation | 2 | 2019 | 1099 | 0.180 |
Why?
|
| Cerebellum | 2 | 2019 | 91 | 0.180 |
Why?
|
| Biosensing Techniques | 1 | 2022 | 113 | 0.180 |
Why?
|
| Phenotype | 1 | 2024 | 1137 | 0.180 |
Why?
|
| Dimethyl Fumarate | 1 | 2020 | 8 | 0.180 |
Why?
|
| Immunoglobulin G | 2 | 2020 | 446 | 0.180 |
Why?
|
| Familial Mediterranean Fever | 1 | 2020 | 9 | 0.170 |
Why?
|
| Cytokines | 1 | 2024 | 912 | 0.170 |
Why?
|
| Phosphate-Binding Proteins | 1 | 2020 | 18 | 0.170 |
Why?
|
| Young Adult | 6 | 2020 | 4267 | 0.170 |
Why?
|
| Encephalomyelitis, Autoimmune, Experimental | 1 | 2020 | 57 | 0.170 |
Why?
|
| Pyroptosis | 1 | 2020 | 31 | 0.170 |
Why?
|
| Microglia | 2 | 2023 | 230 | 0.170 |
Why?
|
| Cysteine | 1 | 2020 | 107 | 0.170 |
Why?
|
| Immunoglobulin M | 1 | 2020 | 114 | 0.170 |
Why?
|
| Anticonvulsants | 1 | 2019 | 88 | 0.160 |
Why?
|
| Movement | 1 | 2020 | 149 | 0.160 |
Why?
|
| Seizures | 1 | 2019 | 113 | 0.160 |
Why?
|
| Raynaud Disease | 1 | 2018 | 4 | 0.150 |
Why?
|
| Alcoholism | 1 | 2021 | 309 | 0.150 |
Why?
|
| Salivary Glands, Minor | 1 | 2018 | 3 | 0.150 |
Why?
|
| Urinary Bladder, Neurogenic | 1 | 2018 | 6 | 0.150 |
Why?
|
| Primary Dysautonomias | 1 | 2018 | 7 | 0.150 |
Why?
|
| Neuralgia | 1 | 2018 | 20 | 0.150 |
Why?
|
| Sensation Disorders | 1 | 2018 | 21 | 0.150 |
Why?
|
| Antibodies, Antinuclear | 1 | 2018 | 36 | 0.150 |
Why?
|
| Physicians | 1 | 2023 | 435 | 0.150 |
Why?
|
| Syncope | 1 | 2018 | 41 | 0.150 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2020 | 327 | 0.150 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2023 | 648 | 0.150 |
Why?
|
| Migraine Disorders | 1 | 2018 | 39 | 0.150 |
Why?
|
| Antibodies, Viral | 1 | 2020 | 292 | 0.150 |
Why?
|
| Aged | 10 | 2024 | 13416 | 0.150 |
Why?
|
| Natalizumab | 2 | 2014 | 11 | 0.140 |
Why?
|
| Neuroimaging | 1 | 2019 | 143 | 0.140 |
Why?
|
| Cohort Studies | 3 | 2020 | 2374 | 0.140 |
Why?
|
| Fatal Outcome | 2 | 2016 | 116 | 0.140 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 2 | 2014 | 57 | 0.140 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 192 | 0.140 |
Why?
|
| Rituximab | 2 | 2014 | 80 | 0.140 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 205 | 0.140 |
Why?
|
| Patient Care Planning | 1 | 2017 | 84 | 0.140 |
Why?
|
| Basigin | 1 | 2016 | 3 | 0.140 |
Why?
|
| Mothers | 1 | 2020 | 255 | 0.140 |
Why?
|
| Gray Matter | 1 | 2016 | 31 | 0.130 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2016 | 50 | 0.130 |
Why?
|
| Interview, Psychological | 1 | 2016 | 73 | 0.130 |
Why?
|
| Tertiary Care Centers | 1 | 2016 | 100 | 0.130 |
Why?
|
| Recurrence | 3 | 2025 | 603 | 0.130 |
Why?
|
| Brain | 3 | 2023 | 1488 | 0.120 |
Why?
|
| Immunoglobulin Heavy Chains | 1 | 2015 | 42 | 0.120 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2015 | 29 | 0.120 |
Why?
|
| Patient Participation | 1 | 2017 | 216 | 0.120 |
Why?
|
| Comorbidity | 2 | 2016 | 1078 | 0.120 |
Why?
|
| Infliximab | 1 | 2015 | 49 | 0.120 |
Why?
|
| Psychotic Disorders | 1 | 2016 | 149 | 0.120 |
Why?
|
| Methotrexate | 1 | 2015 | 76 | 0.120 |
Why?
|
| Interferon beta-1a | 3 | 2020 | 9 | 0.120 |
Why?
|
| DNA Mutational Analysis | 1 | 2015 | 188 | 0.120 |
Why?
|
| Prevalence | 2 | 2016 | 1252 | 0.120 |
Why?
|
| Body Fluids | 1 | 2014 | 22 | 0.120 |
Why?
|
| Research Report | 1 | 2014 | 26 | 0.110 |
Why?
|
| Methylprednisolone | 1 | 2014 | 32 | 0.110 |
Why?
|
| Glycogen Storage Disease Type IV | 1 | 2014 | 2 | 0.110 |
Why?
|
| Glycogen Debranching Enzyme System | 1 | 2014 | 3 | 0.110 |
Why?
|
| Prednisone | 1 | 2014 | 85 | 0.110 |
Why?
|
| Self Report | 1 | 2016 | 359 | 0.110 |
Why?
|
| Neuronal Plasticity | 1 | 2015 | 141 | 0.110 |
Why?
|
| Health Personnel | 1 | 2017 | 342 | 0.110 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2015 | 263 | 0.110 |
Why?
|
| Decision Making | 1 | 2017 | 395 | 0.110 |
Why?
|
| Hypertrophy | 1 | 2013 | 29 | 0.110 |
Why?
|
| Treatment Outcome | 3 | 2025 | 5284 | 0.110 |
Why?
|
| Nucleosomes | 1 | 2015 | 184 | 0.110 |
Why?
|
| Brain Neoplasms | 1 | 2016 | 305 | 0.110 |
Why?
|
| Hydroxybutyrates | 2 | 2025 | 10 | 0.100 |
Why?
|
| Nervous System Diseases | 1 | 2014 | 104 | 0.100 |
Why?
|
| Muscle Weakness | 1 | 2012 | 29 | 0.100 |
Why?
|
| Nitriles | 2 | 2025 | 62 | 0.100 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2014 | 164 | 0.100 |
Why?
|
| Muscular Atrophy, Spinal | 1 | 2012 | 19 | 0.100 |
Why?
|
| Histones | 1 | 2015 | 458 | 0.100 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2015 | 619 | 0.090 |
Why?
|
| Chromatin | 1 | 2015 | 599 | 0.090 |
Why?
|
| Practice Guidelines as Topic | 1 | 2014 | 705 | 0.080 |
Why?
|
| Neurons | 1 | 2015 | 863 | 0.080 |
Why?
|
| Leukocytes, Mononuclear | 2 | 2023 | 238 | 0.080 |
Why?
|
| Depressive Disorder, Major | 1 | 2011 | 245 | 0.070 |
Why?
|
| Multimodal Imaging | 2 | 2019 | 66 | 0.070 |
Why?
|
| Follow-Up Studies | 3 | 2020 | 2337 | 0.070 |
Why?
|
| Incidental Findings | 1 | 2006 | 42 | 0.060 |
Why?
|
| HIV Infections | 1 | 2012 | 913 | 0.060 |
Why?
|
| Case-Control Studies | 2 | 2020 | 1051 | 0.060 |
Why?
|
| Child | 3 | 2020 | 4174 | 0.060 |
Why?
|
| Acetamides | 1 | 2024 | 12 | 0.060 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2016 | 446 | 0.060 |
Why?
|
| Prospective Studies | 2 | 2023 | 3067 | 0.060 |
Why?
|
| Disability Evaluation | 1 | 2025 | 199 | 0.050 |
Why?
|
| Interferon-beta | 2 | 2014 | 76 | 0.050 |
Why?
|
| Pyridines | 1 | 2024 | 98 | 0.050 |
Why?
|
| Contrast Media | 1 | 2006 | 408 | 0.050 |
Why?
|
| Aged, 80 and over | 2 | 2020 | 5128 | 0.050 |
Why?
|
| Hemorrhage | 1 | 2025 | 260 | 0.050 |
Why?
|
| Blood Proteins | 1 | 2023 | 75 | 0.050 |
Why?
|
| Double-Blind Method | 1 | 2025 | 715 | 0.050 |
Why?
|
| Antigens, CD20 | 1 | 2023 | 14 | 0.050 |
Why?
|
| Myelin Sheath | 1 | 2023 | 34 | 0.050 |
Why?
|
| Cerebral Cortex | 1 | 2024 | 248 | 0.050 |
Why?
|
| Metabolome | 1 | 2022 | 27 | 0.050 |
Why?
|
| Plasma | 1 | 2022 | 35 | 0.050 |
Why?
|
| Gadolinium | 1 | 2023 | 103 | 0.050 |
Why?
|
| Fatigue | 1 | 2023 | 103 | 0.050 |
Why?
|
| Albumins | 1 | 2022 | 34 | 0.050 |
Why?
|
| Neuropsychological Tests | 1 | 2023 | 371 | 0.050 |
Why?
|
| Social Class | 1 | 2021 | 122 | 0.050 |
Why?
|
| Flow Cytometry | 1 | 2023 | 644 | 0.050 |
Why?
|
| Citric Acid Cycle | 1 | 2020 | 26 | 0.040 |
Why?
|
| T-Lymphocytes | 2 | 2016 | 986 | 0.040 |
Why?
|
| Macrophage Activation | 1 | 2020 | 118 | 0.040 |
Why?
|
| Anthropometry | 1 | 2020 | 78 | 0.040 |
Why?
|
| Mice, Mutant Strains | 1 | 2020 | 297 | 0.040 |
Why?
|
| Foot | 1 | 2020 | 41 | 0.040 |
Why?
|
| Hand | 1 | 2020 | 67 | 0.040 |
Why?
|
| Lower Extremity | 1 | 2021 | 152 | 0.040 |
Why?
|
| Caspases | 1 | 2020 | 166 | 0.040 |
Why?
|
| Walking | 1 | 2021 | 228 | 0.040 |
Why?
|
| Severity of Illness Index | 2 | 2016 | 1479 | 0.040 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2020 | 258 | 0.040 |
Why?
|
| Mental Health | 1 | 2021 | 335 | 0.040 |
Why?
|
| Betacoronavirus | 1 | 2020 | 166 | 0.040 |
Why?
|
| HEK293 Cells | 1 | 2020 | 587 | 0.040 |
Why?
|
| Algorithms | 1 | 2023 | 976 | 0.040 |
Why?
|
| Disease Progression | 2 | 2014 | 1122 | 0.040 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2021 | 450 | 0.030 |
Why?
|
| Lipopolysaccharides | 1 | 2020 | 627 | 0.030 |
Why?
|
| Retrospective Studies | 2 | 2022 | 6071 | 0.030 |
Why?
|
| Patient Preference | 1 | 2017 | 78 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2017 | 245 | 0.030 |
Why?
|
| Inflammasomes | 1 | 2020 | 324 | 0.030 |
Why?
|
| CD28 Antigens | 1 | 2016 | 60 | 0.030 |
Why?
|
| Logistic Models | 1 | 2020 | 1232 | 0.030 |
Why?
|
| Clinical Decision-Making | 1 | 2017 | 146 | 0.030 |
Why?
|
| Focus Groups | 1 | 2017 | 288 | 0.030 |
Why?
|
| Antibodies | 1 | 2016 | 179 | 0.030 |
Why?
|
| Infant | 1 | 2020 | 1486 | 0.030 |
Why?
|
| Pandemics | 1 | 2020 | 615 | 0.030 |
Why?
|
| Adolescent | 2 | 2016 | 5824 | 0.030 |
Why?
|
| Multigene Family | 1 | 2015 | 92 | 0.030 |
Why?
|
| Frontal Lobe | 1 | 2015 | 64 | 0.030 |
Why?
|
| Fetus | 1 | 2015 | 93 | 0.030 |
Why?
|
| Socioeconomic Factors | 1 | 2017 | 741 | 0.030 |
Why?
|
| Animals | 3 | 2020 | 19651 | 0.030 |
Why?
|
| Macrophages | 1 | 2020 | 1015 | 0.030 |
Why?
|
| Patient-Centered Care | 1 | 2017 | 246 | 0.030 |
Why?
|
| Mice | 2 | 2020 | 10292 | 0.030 |
Why?
|
| JC Virus | 1 | 2014 | 23 | 0.030 |
Why?
|
| Genetic Carrier Screening | 1 | 2014 | 14 | 0.030 |
Why?
|
| Polyomavirus Infections | 1 | 2014 | 46 | 0.030 |
Why?
|
| Lymphocyte Activation | 1 | 2016 | 743 | 0.030 |
Why?
|
| Spinocerebellar Ataxias | 1 | 2014 | 10 | 0.030 |
Why?
|
| Homozygote | 1 | 2014 | 114 | 0.030 |
Why?
|
| Statistics as Topic | 1 | 2014 | 146 | 0.030 |
Why?
|
| Leukoencephalopathies | 1 | 2014 | 24 | 0.030 |
Why?
|
| Hippocampus | 1 | 2015 | 246 | 0.030 |
Why?
|
| Age of Onset | 1 | 2014 | 170 | 0.030 |
Why?
|
| DNA, Viral | 1 | 2014 | 223 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2020 | 3231 | 0.030 |
Why?
|
| Riluzole | 1 | 2012 | 7 | 0.030 |
Why?
|
| Occupational Therapy | 1 | 2012 | 12 | 0.030 |
Why?
|
| Arm | 1 | 2012 | 42 | 0.030 |
Why?
|
| Pregnancy | 1 | 2020 | 2202 | 0.030 |
Why?
|
| Physical Therapy Modalities | 1 | 2012 | 45 | 0.030 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2012 | 93 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2015 | 1093 | 0.020 |
Why?
|
| Neuroprotective Agents | 1 | 2012 | 72 | 0.020 |
Why?
|
| Epigenesis, Genetic | 1 | 2015 | 357 | 0.020 |
Why?
|
| Interferon-gamma | 1 | 2014 | 551 | 0.020 |
Why?
|
| Viral Load | 1 | 2012 | 220 | 0.020 |
Why?
|
| Acute Disease | 1 | 2014 | 660 | 0.020 |
Why?
|
| Amyotrophic Lateral Sclerosis | 1 | 2016 | 480 | 0.020 |
Why?
|
| Transcription, Genetic | 1 | 2015 | 844 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2015 | 1782 | 0.020 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2011 | 379 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2014 | 1921 | 0.020 |
Why?
|
| United States | 1 | 2020 | 7390 | 0.020 |
Why?
|
| Time Factors | 1 | 2014 | 3617 | 0.020 |
Why?
|